Texas-Mexico Border Residence Linked to Worse Survival in Children With ALL
Living along the Texas-Mexico border is associated with worse survival in children diagnosed with acute lymphoblastic leukemia.
Diagnosis & Disease Information
Chest CT Prior to Allo-HSCT Deemed Beneficial for Spotting Abnormalities
Patients with abnormal chest CTs had worse overall survival, nonrelapse mortality, and pulmonary-related death after allo-HSCT.
Hispanic Patients May Have Increased Risk of CRS After CAR T-Cell Therapy
Researchers sought to determine whether race, ethnicity, or BMI would have an impact on CAR T-cell therapy outcomes in patients with B-ALL.
Olverembatinib Shows Promise in TKI-Resistant CML and Ph+ ALL
Olverembatinib has demonstrated antitumor activity in patients with chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia.
CAR-T Therapy in Pediatric Leukemia: Past, Present, and Future
Prior to the introduction of CAR T-cell therapy, pediatric patients with ALL had limited treatment options for relapsed or refractory disease.
Blinatumomab-Based Consolidation Deemed New Standard Care for Adults With MRD-Negative B-ALL
Blinatumomab-based consolidation is a new standard of care for ALL patients with MRD negativity after induction and intensification, researchers say.
Ponatinib Plus Blinatumomab May Reduce Need for HSCT in Ph+ ALL
Combination ponatinib and blinatumomab produced durable responses in patients with newly diagnosed Ph+ acute lymphoblastic leukemia in a phase 2 trial.
Pediatric Cancer Survivors Experience Premature Aging
Young adult survivors of pediatric cancer experience significant premature aging, a retrospective study suggests.
FDA Approves Additional Dosing Schedule for Rylaze
The new dosing option was approved based on data from a phase 2/3 trial.
UCB HSCT May Be Effective Alternative to MS HSCT in Adult B-ALL
Unrelated cord blood transplant can result in comparable outcomes as matched sibling donor transplant in adults with B-cell acute lymphoblastic leukemia.
- Loading...
Loading...
Next post in Hematologic Cancers
Loading... 
Loading...